Univariate analyses among patients who underwent allogeneic HCT for a therapy-related MDS or t-AML
| Outcome . | No. evaluable . | Prob (95% CI) . |
|---|---|---|
| Acute GVHD at 100 d (grades II-IV) | 856 | 39 (35-42) |
| Chronic GVHD | 846 | |
| At 1 y | 27 (24-30) | |
| At 3 y | 29 (26-33) | |
| At 5 y | 30 (27-33) | |
| Treatment-related mortality | 857 | |
| At 1 y | 41 (38-44) | |
| At 3 y | 46 (42-49) | |
| At 5 y | 48 (44-51) | |
| Relapse | 857 | |
| At 1 y | 27 (24-30) | |
| At 3 y | 31 (27-34) | |
| At 5 y | 31 (28-34) | |
| Disease-free survival | 857 | |
| At 1 y | 32 (29-36) | |
| At 3 y | 24 (21-27) | |
| At 5 y | 21 (18-24) | |
| Overall survival | 868 | |
| At 1 y | 37 (34-41) | |
| At 3 y | 25 (22-28) | |
| At 5 y | 22 (19-26) |
| Outcome . | No. evaluable . | Prob (95% CI) . |
|---|---|---|
| Acute GVHD at 100 d (grades II-IV) | 856 | 39 (35-42) |
| Chronic GVHD | 846 | |
| At 1 y | 27 (24-30) | |
| At 3 y | 29 (26-33) | |
| At 5 y | 30 (27-33) | |
| Treatment-related mortality | 857 | |
| At 1 y | 41 (38-44) | |
| At 3 y | 46 (42-49) | |
| At 5 y | 48 (44-51) | |
| Relapse | 857 | |
| At 1 y | 27 (24-30) | |
| At 3 y | 31 (27-34) | |
| At 5 y | 31 (28-34) | |
| Disease-free survival | 857 | |
| At 1 y | 32 (29-36) | |
| At 3 y | 24 (21-27) | |
| At 5 y | 21 (18-24) | |
| Overall survival | 868 | |
| At 1 y | 37 (34-41) | |
| At 3 y | 25 (22-28) | |
| At 5 y | 22 (19-26) |
HCT indicates hematopoietic cell transplantation; MDS, myelodysplastic syndrome; t-AML, therapy-related acute myeloid leukemia; GVHD, graft-versus-host disease; and Prob, probability.